
A development milestone for a specific injury group
The designation concerns chronic traumatic cervical spinal cord injuries with some preserved motor function. NervGen bases its announcement on early data from the CONNECT SCI trial, including improvements in functional hand use.
Phase 3 trial to examine efficacy and safety
The RESTORE trial is recruiting in the United States and Canada. Around 150 participants are planned; NVG-291 is being compared with a placebo. The study is intended to determine whether the earlier findings are confirmed in a larger trial.
The FDA designation is intended to accelerate development and review. It is not drug approval or evidence of a cure.
Wings for Life supports the research
Wings for Life supports CONNECT SCI. In the announcement, Andrew Wagner, CEO of Wings for Life USA, highlights the importance of potential progress for independence and quality of life in everyday activities.
Visit the Wings for Life foundation